ArticleCancer medicine2018
Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma.
Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 64 citations in OpenAlex.
- Article
- C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients.Asia-Pacific journal of clinical oncology · 2025Article
- Establishment of a prognostic signature and immune infiltration characteristics for uterine corpus endometrial carcinoma based on a disulfidptosis/ferroptosis-associated signature.Frontiers in immunology · 2025Article
- Review
- Physiological Functions of the Volume-Regulated Anion Channel VRAC/LRRC8 and the Proton-Activated Chloride Channel ASOR/TMEM206.Handbook of experimental pharmacology · 2024Article
- Article
- Identifying a molecular profile to predict the risk of recurrence in high-intermediate risk endometrial cancer.Cancer medicine · 2021Article
- Article
- Development of a seven-gene tumor immune microenvironment prognostic signature for high-risk grade III endometrial cancer.Molecular therapy oncolytics · 2021Article
- Prognostic Biomarker-Based Identification of Drugs for Managing the Treatment of Endometrial Cancer.Molecular diagnosis & therapy · 2021Article
- Mouse Models of Human Proprotein Convertase Insufficiency.Endocrine reviews · 2021Review
- Identification of an immune-related risk signature and nomogram predicting the overall survival in patients with endometrial cancer.Journal of gynecologic oncology · 2021Article
- Prognostic biomarkers for predicting papillary thyroid carcinoma patients at high risk using nine genes of apoptotic pathway.PloS one · 2021Article
- Alterations in the CaExploration of targeted anti-tumor therapy · 2021Article
- The role of an immune signature for prognosis and immunotherapy response in endometrial cancer.American journal of translational research · 2021Article
- Identification of a Metabolism-Related Signature for the Prediction of Survival in Endometrial Cancer Patients.Frontiers in oncology · 2021Article
- Identification of prognostic biomarkers for major subtypes of non-small-cell lung cancer using genomic and clinical data.Journal of cancer research and clinical oncology · 2020Article
- Article
- Article
- Novel miRNA markers for the diagnosis and prognosis of endometrial cancer.Journal of cellular and molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine corpus endometrial carcinoma (UCEC) is frequently diagnosed among women worldwide. However, there are different prognostic outcomes because of heterogeneity. Thus, the aim of the current study was to identify a gene signature that can predict the prognosis of patients with UCEC. UCEC gene expression profiles were first downloaded from the The Cancer Genome Atlas (TCGA) database. After data processing and forward screening, 11 390 key genes were selected. The UCEC samples were randomly divided into training and testing sets. In total, 996 genes with prognostic value were then examined by univariate Cox survival analysis with a P-value <0.01 in the training set. Next, using robust likelihood-based survival modeling, we developed a six-gene signature (CTSW, PCSK4, LRRC8D, TNFRSF18, IHH, and CDKN2A) with a prognostic function in UCEC. A prognostic risk score system was developed by multivariate Cox proportional hazard regression based on this six-gene signature. According to the Kaplan-Meier curve, patients in the high-risk group had significantly poorer overall survival (OS) outcomes than those in the low-risk group (log-rank test P-value <0.0001). This signature was further validated in the testing dataset and the entire TCGA dataset. In conclusion, we conducted an integrated study to develop a six-gene signature for the prognostic prediction of patients with UCEC. Our findings may provide novel biomarkers for prognosis and have significant implications in the understanding of therapeutic targets for UCEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.